A Targeted Peptide Antibiotic Kills C. difficile in the Gut — but Only When Delivered Rectally

The researchers tested thuricin CD delivery through three approaches: (1) in vitro and in vivo enzyme digestion tests using porcine gastrointestinal models to assess peptide stability, (2) oral spore feeding in 30 mice to see if the producing bacterium could generate thuricin in the gut, and (3) rectal administration of thuricin CD in 40 mice infected with C. difficile ribotype 027, monitoring bacterial shedding at 1, 6, 12, and 24 hours post-treatment.

C. difficile infections cause severe diarrhea and colitis, particularly in hospitalized patients on antibiotics. Current treatments often use broad-spectrum antibiotics that damage beneficial gut bacteria and lead to high relapse rates. A narrow-spectrum peptide like thuricin CD that selectively kills C. difficile while sparing other gut bacteria could represent a fundamentally different treatment approach — if the delivery challenge can be solved.

Antibiotic resistance and C. difficile recurrence are major clinical problems. Narrow-spectrum antimicrobial peptides like thuricin CD represent a promising alternative to broad-spectrum antibiotics because they target specific pathogens without collateral damage to the gut microbiome. This study highlights both the potential and the delivery challenges that must be overcome before peptide-based antibiotics can become practical treatments.

This was an animal study in mice and pigs, so results may not translate directly to humans. The rectal delivery route, while effective, is less convenient than oral administration. The study did not assess long-term outcomes, relapse rates, or effects on the broader gut microbiome. Sample sizes were modest (10 mice per group in the rectal study).